Piramal Pharma Solutions, a contract development and manufacturing organisation, has announced an $80m investment to expand its sterile injectables facility in Lexington, Kentucky, in the US.
The expansion aims to bolster the company's manufacturing capabilities and capacity to meet the increasing market demand for sterile injectable drug products.
The site, which is a key component of the company's integrated antibody-drug conjugate (ADC) development and manufacturing programme, ADCelerate, will see an addition of 24,000ft² of manufacturing space.
This includes a new laboratory and advanced machinery, addition of a new filling line, two commercial-size lyophilisers, an external vial washer, and a capping machine.
Piramal Pharma chairperson Nandini Piramal said: “This expansion represents a strategic investment in the future of Piramal Pharma.
“Filling the commercial manufacturing gap enables the Lexington site to access the rapidly expanding injectables market and establish itself as a key player in the segment.”
Currently, the Lexington facility has the capability to produce 104 product batches annually at peak levels.
With the completion of the expansion projected for the first quarter of 2027, the site's capacity is expected to more than double, allowing for over 240 batches each year.
Several clients have already committed to commercialising their products at the expanded Lexington site.
The expansion is set to create more than 40 full-time jobs, significantly contributing to the local economy and promoting a diverse workforce.
Kentucky governor Andy Beshear said: “Kentucky's business-friendly climate, prime location and access to resources make it an ideal destination for companies to locate, expand and thrive.
“The decision by Piramal Pharma Solutions' leadership to expand and reinvest here is a testament to their trust and belief in what this great state has to offer. I want to thank the company's leaders and wish Piramal Pharma continued success in Lexington.”
Last month, the Science Based Targets initiative confirmed that Piramal Pharma's short-term targets for reducing greenhouse gas emissions met scientific standards.
